**Core Concept**
Prasugrel is a thienopyridine antiplatelet agent similar to clopidogrel, used to prevent thrombotic events in patients with acute coronary syndromes. The key difference lies in their pharmacokinetics and pharmacodynamics.

**Why the Correct Answer is Right**
Prasugrel has a more rapid onset of action and higher platelet inhibition compared to clopidogrel due to its more efficient conversion to its active metabolite. This is because prasugrel undergoes a single metabolic step to form its active metabolite, whereas clopidogrel requires two metabolic steps. As a result, prasugrel achieves higher platelet inhibition and a more consistent response among patients.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because prasugrel is actually associated with a higher risk of bleeding compared to clopidogrel, not a lower risk.
**Option B:** This option is incorrect because prasugrel is not more effective in patients with a history of stroke or transient ischemic attack; in fact, it may increase the risk of stroke in these patients.
**Option C:** This option is incorrect because prasugrel is not less expensive than clopidogrel; in fact, it is often more expensive due to its more complex synthesis.

**Clinical Pearl / High-Yield Fact**
It is essential to note that prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke, as it may increase the risk of hemorrhagic stroke.

**Correct Answer:** C. Prasugrel has a more rapid onset of action and higher platelet inhibition compared to clopidogrel.